Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) PIK3CA Antibodies:
anti-Human PIK3CA Antibodies:
anti-Rat (Rattus) PIK3CA Antibodies:
Go to our pre-filtered search.
Human Monoclonal PIK3CA Primary Antibody for ICC, FACS - ABIN969555
Edwards, Witherspoon, Wang, Afrasiabi, Pham, Birnbaumer, Lipkin: Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer. in Cancer research 2009
Show all 3 Pubmed References
Human Polyclonal PIK3CA Primary Antibody for FACS, IHC (p) - ABIN1882113
Singh, Reddy, Goberdhan, Walsh, Dao, Ngai, Chou, O-Charoenrat, Levine, Rao, Stoffel: p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. in Genes & development 2002
Show all 3 Pubmed References
Human Polyclonal PIK3CA Primary Antibody for ELISA, IHC - ABIN188684
López-Knowles, Hernández, Malats, Kogevinas, Lloreta, Carrato, Tardón, Serra, Real: PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. in Cancer research 2006
Show all 2 Pubmed References
Human Polyclonal PIK3CA Primary Antibody for IF (p), IHC (p) - ABIN677198
Paul-Samojedny, Suchanek, Borkowska, Pude?ko, Owczarek, Kowalczyk, Machnik, Fila-Dani?ow, Kowalski: Knockdown of AKT3 (PKB?) and PI3KCA suppresses cell viability and proliferation and induces the apoptosis of glioblastoma multiforme T98G cells. in BioMed research international 2014
Human Polyclonal PIK3CA Primary Antibody for ELISA, IHC - ABIN334459
Abubaker, Bavi, Al-Haqawi, Jehan, Munkarah, Uddin, Al-Kuraya: PIK3CA alterations in Middle Eastern ovarian cancers. in Molecular cancer 2009
Show all 2 Pubmed References
Human Polyclonal PIK3CA Primary Antibody for WB - ABIN3043462
Wang, Sun, Li, Dong, Li, Zhao: Resveratrol attenuates intermittent hypoxia-induced insulin resistance in rats: involvement of Sirtuin 1 and the phosphatidylinositol-4,5-bisphosphate 3-kinase/AKT pathway. in Molecular medicine reports 2014
Here, we describe a role for PI3K/AKT (show AKT1 Antibodies) in the regulation of TRF1 (show TERF1 Antibodies), an essential component of the shelterin complex. PI3K and AKT (show AKT1 Antibodies) chemical inhibitors reduce TRF1 (show TERF1 Antibodies) telomeric foci and lead to increased telomeric DNA damage and fragility. We identify the PI3Kalpha isoform as responsible for this TRF1 (show TERF1 Antibodies) inhibition.
The data establish oncogenic PIK3CA mutations as a cause of glutamine (show GFPT1 Antibodies) dependency in colorectal cancer.
High PI3k expression is associated with gastrointestinal stromal tumor.
High PI3K expression is sensitive to initial injury intensity induced by freeze damage.
excessive proliferation of endometrial epithelial cells was observed in Pik3cad/d mice. Our studies suggest that Pik3ca has a critical role in uterine gland development and female fertility
Long latency DMBA induced mouse mammary tumors reproduce the molecular profile of human luminal breast carcinomas, displaying a high incidence of activating Pik3caH1047 and loss of function Pten mutations.
Data show that the phosphoinositide 3-kinase (PI3K) inhibitor BKM120 led to a precipitous drop in DNA synthesis within 8 h of drug treatment, whereas DNA synthesis in normal tissues was less affected.
Using genetic inactivation of the growth and metabolism regulator, Pik3ca (encoding PIK3CA also known as p110alpha, alpha/+), the interplay between the maternal genome and the fetal genome on placental phenotype, was examined.
these results identify the PI3K-GSK3-SMAD1 (show SMAD1 Antibodies) axis as a central node integrating multiple signaling networks that govern bone formation and homeostasis.
Data suggest a critical role for KDM3A (show KDM3A Antibodies) in the PI3K/AP-1 (show JUN Antibodies) oncogenic axis and propose a novel strategy for inhibition of KDM3A (show KDM3A Antibodies) against liver tumor development under PI3K pathway activation.
The PIK3CA and PIK3R1 impactful mutations exhibit a mutually exclusive pattern, leading to oncogenesis and hyperactivity of PI3K pathway in breast cancer.
PIK3CA mutation is associated with decreased risk of peritoneal metastases in chemo-resistant metastatic colorectal cancer.
High PIK3CA expression is associated with metastasis via epithelialmesenchymal transition carcinoma in colorectal cancer.
High PI3K expression is associated with periodontitis.
We validated the presence of IDH2 (show IDH2 Antibodies) R172 hotspot mutations and PIK3CA hotspot mutations in 100% and 67% of solid papillary breast carcinoma with reverse polarity tested, respectively
High PIK3CA expression is associated with metastasis in colon cancer.
In this study, we used the Ion Personal Genome Machine (PGM) and Ion Torrent Ampliseq Cancer panel to sequence hotspot regions from PIK3CA, AKT and PTEN genes to identify genetic mutations in 39 samples of TNBC subtype from Moroccan patients and to correlate the results with clinical-pathologic data
Our results indicate that low-grade adenosquamous carcinoma of the breast of the breast is a low-grade triple-negative breast cancer that harbours a basal-like phenotype with no androgen receptor (show AR Antibodies) expression, and shows a high rate of PIK3CA mutations
Multivariate analyses revealed that the PIK3CA mutation and clinical T stage were independent favorable prognostic factors (hazard ratio 0.34, 95% confidence interval: 0.12-0.96, p = 0.042). PIK3CA mutations were significantly associated with APC (show APC Antibodies) alterations (p = 0.0007) and BRAF (show BRAF Antibodies) mutations (p = 0.0090).
higher frequency of ESR1 (show ESR1 Antibodies) and PIK3CA mutations in the plasma than in the serum in 33 MBC (show DOCK2 Antibodies) patients; therefore, serum samples should not be considered the preferred source of cfDNA.
There are multiple conformations in equilibrium during the course of PI3K SH3 domain (show ITSN1 Antibodies) unfolding.
PI3K has a role in activation of 5'-AMP (show TMPRSS5 Antibodies)-activated kinase during hypoxia-reoxygenation of bovine aortic endothelial cells
Production of PtdIns3P by PI3K-C2alpha (show PIK3C2A Antibodies) is required for acquisition of fusion competence in neurosecretion.
crystallographic and biochemical approaches used to gain insight into activating mutations in two noncatalytic p110alpha domains-the adaptor-binding and the helical domains
Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers.
phosphoinositide-3-kinase, catalytic, alpha polypeptide
, Phosphoinositide-3-kinase, catalytic, alpha polypeptide
, PI3-kinase subunit alpha
, phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha
, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
, phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha
, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
, phosphoinositide-3-kinase catalytic alpha polypeptide
, ptdIns-3-kinase subunit alpha
, ptdIns-3-kinase subunit p110-alpha
, serine/threonine protein kinase PIK3CA
, PI3-kinase p110 subunit alpha
, phosphatidylinositol 3-kinase, catalytic, 110-KD, alpha
, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide
, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, alpha isoform
, ptdIns-3-kinase p110
, phosphoinositide 3-kinase catalytic subunit